ATLa, an Aspirin-Triggered Lipoxin A4 Synthetic Analog, Prevents the Inflammatory and Fibrotic Effects of Bleomycin-Induced Pulmonary Fibrosis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Despite an increase in the knowledge of mechanisms and mediators involved in pulmonary fibrosis, there are no successful therapeutics available. Lipoxins (LX) and their 15-epimers, aspirin-triggered LX (ATL), are endogenously produced eicosanoids with potent anti-inflammatory and proresolution effects. To date, few studies have been performed regarding their effect on pulmonary fibrosis. In the present study, using C57BL/6 mice, we report that bleomycin (BLM)-induced lung fibrosis was prevented by the concomitant treatment with an ATL synthetic analog, ATLa, which reduced inflammation and matrix deposition. ATLa inhibited BLM-induced leukocyte accumulation and alveolar collapse as evaluated by histology and morphometrical analysis. Moreover, Sirius red staining and lung hydroxyproline content showed an increased collagen deposition in mice receiving BLM alone that was decreased upon treatment with the analog. These effects resulted in benefits to pulmonary mechanics, as ATLa brought to normal levels both lung resistance and compliance. Furthermore, the analog improved mouse survival, suggesting an important role for the LX pathway in the control of disease establishment and progression. One possible mechanism by which ATLa restrained fibrosis was suggested by the finding that BLM-induced myofibroblast accumulation/differentiation in the lung parenchyma was also reduced by both simultaneous and posttreatment with the analog (α-actin immunohistochemistry). Interestingly, ATLa posttreatment (4 days after BLM) showed similar inhibitory effects on inflammation and matrix deposition, besides the TGF-β level reduction in the lung, reinforcing an antifibrotic effect. In conclusion, our findings show that LX and ATL can be considered as promising therapeutic approaches to lung fibrotic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Chua, F., Gauldie, J., & Laurent, G. J. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0062tr · Cited by 305
Mitchell, S., Thomas, G., Harvey, K., Cottell, D., Reville, K., Berlasconi, G., Petasis, N. A., Erwig, L., Rees, A. J., Savill, J., et al. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032417.73640.72 · Cited by 287 · cited 1×
“Metabolically stable synthetic analogs represent useful tools to evaluate the potential of pharmacological manipulation of the inflammatory process as a means to develop new and selective antiinflammatory therapies with reduced toxic side effects (25, 26).”
BackgroundMatrix metalloproteases in aberrant fibrotic tissue remodeling
Pardo, A., & Selman, M. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-012tk · Cited by 260
Cited by
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Specialized pro-resolving mediators: endogenous regulators of infection and inflammation
Basil, M. C., & Levy, B. D. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.4 · Cited by 791
The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution
Serhan, C. N., Chiang, N., & Dalli, J. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.004 · Cited by 583
Serhan, C. N. (2017) · The FASEB Journal · doi:10.1096/fj.201601222r · Cited by 555
Specialized pro-resolving lipid mediators in the inflammatory response: An update
Bannenberg, G., & Serhan, C. N. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.08.002 · Cited by 464
Novel Lipid Mediators and Resolution Mechanisms in Acute Inflammation
Serhan, C. N. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100322 · Cited by 421
Layé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
“…leads to a loss of its activity, the acetylated form of COX-2 leads to the synthesis of AT-LxA4, primarily identified to limit neutrophil activation and recruitment to inflamed tissues (Serhan et al., 2002) with anti-inflammatory and proresolving activities (Ye et al., 2010; Martins et al., 2009).”
BackgroundNovel Lipid Mediators Promote Resolution of Acute Inflammation: Impact of Aspirin and Statins
Spite, M., & Serhan, C. N. (2010) · Circulation Research · doi:10.1161/circresaha.110.223883 · Cited by 365
Chiang, N., & Serhan, C. N. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.03.005 · Cited by 324
Lipoxins and aspirin-triggered lipoxins in resolution of inflammation
Romano, M., Cianci, E., Simiele, F., & Recchiuti, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.083 · Cited by 183
“, 2014), hydrochloric acid, LPS and bleomycin (Martins et al., 2009).”
BackgroundEvaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
Roach, K., Castells, E., Dixon, K., Mason, S., Elliott, G., Marshall, H., Poblocka, M., Macip, S., Richardson, M., Khalfaoui, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.679388 · Cited by 39
Metadata
- Authors
- Martins, V., Valença, S. S., Farias-Filho, F. A., Molinaro, R., Simões, R. L., Ferreira, T. P. T., e Silva, P. M. R., Hogaboam, C. M., Kunkel, S. L., Fierro, I. M., Canetti, C., & Benjamim, C. F.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-05-01
- Volume
- 182
- Issue
- 9
- Pages
- 5374-5381
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1811197614
- Cited by
- 84
- References
- 4
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.